Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Health Catalyst (HCAT) Cash & Equivalents (2018 - 2025)

Health Catalyst (HCAT) has disclosed Cash & Equivalents for 8 consecutive years, with $40.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 87.72% year-over-year to $40.3 million, compared with a TTM value of $40.3 million through Sep 2025, down 87.72%, and an annual FY2024 reading of $249.6 million, up 134.9% over the prior year.
  • Cash & Equivalents was $40.3 million for Q3 2025 at Health Catalyst, down from $50.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $342.0 million in Q1 2025 and bottomed at $40.3 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $173.0 million, with a median of $177.0 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 245.71% in 2024, then crashed 87.72% in 2025.
  • Year by year, Cash & Equivalents stood at $193.2 million in 2021, then plummeted by 39.81% to $116.3 million in 2022, then fell by 8.63% to $106.3 million in 2023, then surged by 134.9% to $249.6 million in 2024, then plummeted by 83.86% to $40.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for HCAT at $40.3 million in Q3 2025, $50.7 million in Q2 2025, and $342.0 million in Q1 2025.